Tag - XBIO

Developments

Xenetic and PeriNess report first patient dosed in investigator-led study at TASMC

Xenetic Biosciences (NASDAQ: XBIO) has announced that its collaboration partner, closely held PeriNess, has informed the company that the first patient has been dosed in an investigator-initiated clinical study...

October 15, 2026

Developments

Xenetic and Santersus enter into definitive share exchange agreement

Xenetic Biosciences (NASDAQ: XBIO) has entered into a definitive share exchange agreement to acquire closely held Santersus in an all-stock transaction, subject to stockholder approval. The combined company is expected...

September 17, 2026

Markets

HCW starts Xenetic Biosciences at buy; PT $2

H.C. Wainwright initiated coverage of Xenetic Biosciences (NASDAQ:XBIO) with a “buy” rating and price target of $2. The stock closed at 86 cents on May 1. The main focus of the company is development of XCART, a CAR-T...

May 4, 2020

Tag - XBIO

Xenetic and PeriNess report first patient dosed in investigator-led study at TASMC

Xenetic and Santersus enter into definitive share exchange agreement

HCW starts Xenetic Biosciences at buy; PT $2

Subscribe